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Standard cytotoxic chemotherapy can initially achieve high response rates, but relapses often occur in patients and represent a
severe clinical problem. As increasing numbers of chemotherapeutic agents are found to have immunostimulatory eﬀects, there is
a growing interest to combine chemotherapy and immunotherapy for synergistic antitumor eﬀects and improved clinical beneﬁts.
Findings from recent studies suggest that highly activated, polyfunctional CD4+ eﬀe c t o rTc e l l sh a v et r e m e n d o u sp o t e n t i a li n
strengthening and sustaining the overall host antitumor immunity in the postchemotherapy window. This review focuses on the
latest progresses regarding the impact of chemotherapy on CD4+ T-cell phenotype and function and discusses the prospect of
exploiting CD4+ T cells to control tumor progression and prevent relapse after chemotherapy.
1.Introduction
As a major treatment modality for many advanced cancers,
conventional chemotherapy can achieve high response rates
but is rarely curative. The mounting evidence that many
chemotherapeutic agents have immunostimulatory eﬀects
has provided a compelling rationale for developing com-
bined chemoimmunotherapy strategy to achieve improved
patient outcomes [1–3]. Current cancer immunotherapies
predominantly rely on CD8+ T cells to ﬁght against tumors.
Although it is increasingly clear that proinﬂammatory CD4+
eﬀector T cells are critical determinants of eﬀective antitu-
mor immune responses [4–9], the utilization of CD4+ T
cell-based immunotherapy in combination with chemother-
apy to control tumor progression and recurrence has not
been fully explored. Nonetheless, a plethora of information
accumulated from preclinical and clinical studies suggests
that these two treatment modalities might be mutually re-
inforcing, and therefore their combination represents an
eﬀective chemoimmunotherapy strategy.
2. Anticancer Drugs and Immune Activation
Anticancer drugs are selected for their cytotoxicity toward
cancerouscells.Althoughsomeanticancerdrugswereknown
to have immune-potentiating eﬀects long time ago [10, 11],
the therapeutic potential of this property has been largely
ignored. As increasing numbers of conventional chemother-
apeutic agents are found to possess immunostimulatory
properties, it has come to the realization in recent years that
elicitation of the host antitumor immunity may constitute
an integral component of the anticancer eﬃcacy of some
antineoplastic agents [12].
Multiple classes of anticancer chemotherapeutic drugs
have been reported to exert immune enhancing eﬀects,
and a number of them have been extensively studied. Cy-
clophosphamide (CTX) is an alkylating agent chemically
related to nitrogen mustard. As a prodrug, CTX is con-
verted into its active metabolite derivative phosphoramide
mustard in the liver. Phosphoramide mustard inhibits DNA
replication by forming crosslinks between (interstrand) and2 Clinical and Developmental Immunology
within (intrastrand) DNA strands. CTX is often used in
combination with other anticancer drugs in the treatment
of lymphomas and some solid tumors. Doxorubicin is
a cytotoxic anthracycline antibiotic. It is known to bind
to nucleic acids by intercalating the DNA strands and
disrupting DNA replication. Doxorubicin is commonly used
to treat hematological malignancies (leukemia, lymphoma,
and multiple myeloma), and many types of solid tumors.
Gemcitabine is a pyrimidine nucleoside analog that acts as
an antimetabolite. Gemcitabine is used in a wide range of
carcinomas, including lung, pancreatic, breast, and bladder
cancer. Paclitaxel and docetaxel belong to the taxane class
of drugs that act as mitotic inhibitors. These drugs cause
cell-cycle arrest by stabilizing GDP-bound tubulin in micro-
tubules, thereby disrupting the process of cell division. They
arecurrentlyusedtotreatpatientswithlung,breast,prostate,
and ovarian cancer. Cisplatin and oxaliplatin are platinum-
based anticancer drugs. These platinum complexes induce
apoptosis in malignant cells by causing crosslinking of DNA.
Althoughtheseanticancerdrugscausetumordestruction
through diﬀerent mechanisms, they share some common
features in exerting immune-enhancing eﬀects.
2.1. Inducing Immunogenic Tumor Cell Death. Tumor cells
killed by anticancer drugs not only provide the source of
tumor antigens but also release “danger signals” that awaken
the innate immune cells, which in turn activate the adaptive
immune system. Studies from Zitvogel’s group have char-
acterized several prominent features of immunogenic cell
death after cytotoxic chemotherapy, including translocation
of calreticulin (CRT), secretion of high-mobility-group box
1 (HMGB1), and release of adenosine triphosphate (ATP) by
dying tumor cells. These studies reported that doxorubicin
induces rapid translocation of the endoplasmic reticulum-
resident protein calreticulin to tumor-cell surface,presenting
a “eat-me” signal for phagocytosis by dendritic cells [13].
HMGB1 released by dying tumor cells after doxorubicin or
oxaliplatin treatment acts upon toll-like receptor 4 (TLR4)
on dendritic cells to initiate eﬃcient antigen processing and
presentationthatinvolvestheMyd88-signalingpathway[14].
Doxorubicin and oxaliplatin can also induce release of ATP
bytumorcells,whichtriggerspurinergicP2RX7receptorson
dendritic cells (DCs) to activate the NOD-like receptor fam-
ily, pyrin-domain-containing protein 3-dependent caspase-
1 activation complex, namely, the NLRP3 inﬂammasome,
which ultimately leads to IL-1β-dependent adaptive immu-
nity [15]. Along the same line, cyclophosphamide has been
recently reported to cause CRT translocation and HMGB1
release in some types of tumor [16, 17]. Furthermore,
it has been shown that tumor-cell apoptosis induced by
gemcitabine can enhance DC cross-presentation of tumor
antigen to CD8+ T cells [18], but it is not yet clear whether
CRT translocation, mobilization of HMGB1, and ATP are
involved in the process.
2.2. Mitigating Immunosuppressive Mechanisms. The ability
of tumors to evade immune destruction is critical for tumor
formation and progression and is now regarded as an emerg-
ing hallmark of cancer [19]. Under the selection pressure
imposed by natural immune surveillance or therapeutic in-
terventions, tumors may avoid immune attacks through pas-
sive mechanisms such as downmodulating the expressions
of the relevant MHC-I molecules and antigens [20, 21].
In addition, tumor cells have evolved to employ multiple
immune regulatory mechanisms to actively attenuate and
subvert antitumor immune responses. Regulatory T cells
(Treg) and myeloid-derived suppressor cells (MDSCs) are
frequently enriched in the tumor microenvironment and
facilitate tumor immune evasion [22]. Some chemothera-
peutic agents can potentiate antitumor immune responses
by directly targeting these immunosuppressive cells. Low-
dose cyclophosphamide (100mg/kg) is capable of depleting
cycling CD4+CD25+ Tregs and inhibiting their suppressive
activity[23,24].Asaresult,theeﬀectoractivitiesofcytotoxic
CD8+ T cells and NK cells are unmasked to control tumor
growth [25–27]. A recent study has suggested that CTX can
preferentially deplete tolerogenic CD8+ lymphoid-resident
DCs, leading to diminished Treg suppression and enhanced
eﬀector T-cell function as manifested by induction of
concomitant immunity in a prophylactic setting [28]. It
is currently unclear whether this mechanism of action is
operative in a therapeutic setting. On a diﬀerent note,
gemcitabine does not deplete Tregs [24] but selectively
reduces CD11b+Gr1+ MDSCs and enhances the antitumor
activities of CD8+ T cells and NK cells [29].
2.3. Creating Lymphopenia and Immunogenic Milieu. Many
anticancer drugs can cause varied degree of lymphodeple-
tion [30]. It has been well established that lymphodeple-
tion induced by chemotherapy or radiotherapy profoundly
enhances the eﬃcacy of adoptive cell therapy (ACT) and
cancer vaccines [31]. This is likely due to the combined
eﬀects of creation of space and increased availability
of stimulatory growth factors that lead to enhanced pro-
liferation and survival of activated T cells [32]. In this
regard, cyclophosphamide is a representative anticancer
drug that causes profound lymphodepletion while creating
an immune milieu rich of type I interferons (IFNs) and
common gamma-chain cytokines (IL2, IL7, and IL15) [33,
34]. Of notice, type I interferons are known to promote DC
maturationandT-celldiﬀerentiation[35–38].IL7isessential
for survival and memory formation of tumor-reactive T
cells, and neutralization of IL7 after CTX administration
diminishes the number of tumor-reactive T cells in an
adoptive transfer model [33]. Besides strengthening the
activities of immune cells, chemotherapy also promotes the
traﬃcking of activated immune cells to the sites of tumor
[33, 39, 40]. Accumulating evidence demonstrates that there
is a surge of proinﬂammatory cytokines/chemokines, such as
GMCSF, IL1β, IL6, and CXCL10, in the postchemotherapy
immune milieu, which may contribute to the recruitment
and retention of tumor-reactive immune cells, including
activated CD8+ and CD4+ T cells, DCs, macrophages, and
neutrophiles, in the tumor microenvironment [15, 17, 34].Clinical and Developmental Immunology 3
2.4. Sensitizing Tumor Cells to Immune Destruction. In ad-
dition to attracting activated immune cells to the tumor
loci, chemotherapy may render tumor cells more susceptible
to immune attack. It has been shown that doxorubicin,
cisplatin, and paclitaxel can sensitize tumor cells to the
cytolytic eﬀect of CD8+ T cells by making them permeable
to granzyme B via mannose-6-phosphate receptors on the
surface of tumor cells [40]. Moreover, chemotherapy with
cyclophosphamide can sensitize tumor cells to TRAIL-
dependent CD8+ T cell-mediated immune destruction [41].
3. Chemotherapy and Antitumor
CD4 Responses
Agreatdealofeﬀorthasbeenfocusedonunderstandinghow
chemotherapypotentiates CD8+ T-cellresponses [27,38,41,
42], mitigates Treg-mediated immune suppression [23, 26,
43], and enhances antigen presentation [13, 14, 28, 44, 45].
Although tumor-reactive CD4+ eﬀector/helper T cells are
increasingly recognized as critical determinants of eﬀective
antitumor immune responses, the eﬀect of chemotherapy
on these cells is largely neglected, and the role of CD4+
T cells in modulating postchemotherapy host immunity is
almost entirely unknown. In the following we mainly focus
on ﬁndings that concern the impact of chemotherapy on the
interactions between tumors and CD4+ T cells.
3.1. CD4+ T Cells Subsets and Their Diverse Roles in
Tumor Immunity. Upon stimulation na¨ ıve CD4+ T cells
diﬀerentiate into eﬀector cells known as T helper (Th) cells.
Originally Th cells were classiﬁed into Th1 and Th2 lineages,
depending on the cytokine proﬁles of the eﬀector cells [46].
With the discovery of new T-cell lineages in recent years,
the Th1/Th2 paradigm has been revised to reﬂect a much
broadened spectrum of CD4+ T-cell subsets. It has now been
established that na¨ ıve CD4+ T cells can diﬀerentiate into
fourmajor lineages,including Th1, Th2, Th17, andTreg cells
[47], and that Th cells are plastic—cells of one lineage can
be converted to another lineage under certain circumstances
[48].
The distinct CD4+ T-cell subsets have varied impact
on tumor growth. Th1 cells, characterized by production
of IFNγ and TNFα, often lead to enhanced activation of
cytotoxic CD8+ T cells, DCs and macrophages, exhibiting
beneﬁcial antitumor eﬀects. In contrast, IL4-producing Th2
cells may promote tumor progression by enhancing the
activity of protumor macrophages [49] although Th2 cells
can also mediate tumor rejection under certain condition
[50]. Currently there is much debate about the role of
Th17 cells in antitumor immunity [51], because both tumor
rejection and tumor promotion involving Th17 cells and
their major product proinﬂammatory cytokine IL17 have
been reported [52–55]. Treg cells act to dampen antitumor
immunity by suppressing the eﬀector functions of a variety
of immune cells, including Th1 cells [56–58], CD8+ T cells
[5], NK cells [59], and tumor-inﬁltrating DCs [60].
3.2. Eﬀect of Chemotherapy on CD4+ T-Cell Eﬀector Develop-
ment. So far, among the aforementioned anticancer drugs,
cyclophosphamide (CTX) appears to be the most eﬀective
one in enhancing antitumor CD4 responses, particularly
when used in combination with adoptive cell therapy (ACT).
It has been demonstrated in various preclinical models that
CTX treatment followed by adoptive transfer of tumor-
reactive CD4+ T cells, either monoclonal T-cell clones
derived from TCR-transgenic mice, or activated polyclonal
CD4+ T cells derived from preimmunized mice, leads
to eradication of established tumors [61–64]. One salient
observation from these studies is that the robust antitumor
eﬀectsareassociatedwiththedevelopmentofTh1antitumor
immunity. In line with an early study showing that CTX
induced a Th2 to Th1 shift in the cytokine proﬁle of
lymphoma-bearing rats [65], we have recently reported in a
mouse lymphoma model that CTX overcomes tumor-driven
aberrant CD4+ T-cell diﬀerentiation and directs CD4+ T
cells to become highly activated polyfunctional eﬀector cells,
marked by their ability to concomitantly produce multiple
Th1-type cytokines including IL2, IFNγ,a n dT N F α [64].
In a mouse melanoma model, Quezada et al. reported that
tumor-speciﬁc CD4+ T cells acquired a similar polyfunc-
tional phenotype in postradiotherapy hosts [66], suggesting
that the immunogenic milieu created by chemotherapy or
radiotherapy may share some common features in terms of
driving CD4+ T-cell eﬀector diﬀerentiation. In addition to
promoting Th1 diﬀerentiation, there is emerging evidence
that CTX also induces Th17 cells [34, 67]. These Th17
cells are likely de novo induced in the postchemotherapy
milieu, because they are not converted from Treg cells [67],
and do not coexpress IFNγ [34]. In contrast, doxorubicin
and oxaliplatin each induces IL17-producing γδT cells but
not Th17 cells [68]. It will be of interest to test additional
anticancer drugs to deﬁne the common features of the drugs
that are capable of driving eﬀector CD4 responses like CTX.
3.3. Mechanisms by Which Anticancer Drugs Modulate CD4
Responses. Even though CTX is by far the most potent CD4-
potentiating anticancer drug demonstrated experimentally,
the cellular and molecular mechanisms underlying its eﬀect
are not well understood. In addition to its well-known eﬀect
of depleting suppressor T cells, accumulating evidence has
established a link between productive CD4+ T-cell responses
andanimmunogenicmilieuinducedbyCTX[17,33,36,64].
The immunogenic milieu is rich of various growth factors
and proinﬂammatory cytokines and chemokines, among
which type I IFNs and IL7 have been shown to exert particu-
larly important immunostimulatory eﬀects. Type I IFNs can
augment immune responses through enhanced stimulation
of dendritic cells [69]. It has been shown that DCs require
type I IFNs to mature and induce CD4+ Th1 immunity
[70]. In the same vein, a recent study has reported that IFNα
enhances T helper cell functions while reducing Treg activity
through modulating APC activation [71]. In addition to
supporting T-cell survival and homeostasis, IL7 has recently
been shown to antagonize cbl-b and TGFβ signaling, two
pathways involved in inhibiting T-cell activation, leading to4 Clinical and Developmental Immunology
augmented Th17 diﬀerentiation [72]. Moreover, it has been
reported that IL7 promotes Th1-like immunity and inhibits
Treg activity [73, 74]. Altogether it is conceivable that CTX’s
multifaceted and dynamic immunomodulatory eﬀects, for
example, depletion of Treg, creation of lymphopenia, and
induction of stimulatory cytokines superimpose to foster a
profoundly immunogenic milieu that drives the develop-
ment of fully diﬀerentiated Th1 or Th17 eﬀector T cells. To
better understand the mechanisms underlying the diverse
CD4+ T-cell diﬀerentiation in postchemotherapy setting,
future studies should dissect the interrelation of the above-
mentioned contributing factors, and their relative contribu-
tion to the functional development of tumor-speciﬁc CD4+
T cells.
3.4. Antitumor Eﬀects of CD4+ Eﬀector T Cells
3.4.1. Activating Tumoricidal CD8 and Macrophages and Sen-
sitizing Tumor Stroma. CD4+ T cells have been regarded as
specialized helper cells that assist in the activation of other
innate and adaptive immune cells. Once properly activated,
CD4+ T cells express an array of eﬀector molecules, includ-
ing CD40L, IL2, IFNγ,a n dT N F α, which play critical roles in
orchestratingeﬀectiveantitumorimmuneresponses.Consis-
tentwiththewell-deﬁnedroleofCD40LintransmittingCD4
help for CD8+ T cells [75–77], it has been shown in diﬀerent
animalmodelsthatactivatedCD4+TcellscanlicenseDCsin
the tumor microenvironment via CD40L-CD40 interaction,
leading to priming of tumor-reactive CD8+ T cells which
in turn mediate long-term protection [78, 79]. In addition
to licensing of DC, some previously unappreciated help
activities of CD4+ T cells have recently been uncovered,
revealing the molecular basis of the once vaguely-deﬁned
“post-licensing” role of CD4+ T cells [80]. For example, it
has been shown that CD4+ eﬀector T cells recruit activated
CD8+ T cells via the action of IFNγ [81, 82]a n dp r o m o t e
CD8+T-cellcytolyticfunctionandproliferationthroughIL2
[82]. Besides targeting tumor cells, CD4+ eﬀector T cells
have been implicated in inhibiting tumor angiogenesis by
acting on tumor stroma via IFNγ [83]. Given that CD8+
T cell-derived TNFα and IFNγ can sensitize tumor stroma
and mediate bystander tumor eradication [84], we speculate
that polyfunctional CD4+ eﬀector T cells have the same
eﬀect because these cells can produce these two cytokines
simultaneously [34]. Notably, it has been reported that Th1-
derived IFNγ also renders macrophages cytotoxic to cancer
cells [6, 85]. Interestingly, Beatty et al. reported that CD40-
activated macrophages become tumoricidal and facilitate
the destruction of tumor stroma in mice and humans
with pancreatic carcinoma [86]. Although this study used
an agonist CD40 antibody to activate macrophages, it is
tempting to speculate that CD40L-expressing CD4+ eﬀector
T cells would achieve similar eﬀects.
3.4.2. Conditioning a Protective Inﬂammatory Milieu. Chem-
otherapy often induces inﬂammation in the tumor microen-
vironment by causing tumor cell death and tissue dam-
age. Paradoxically, many of the proinﬂammatory cytokines
induced after chemotherapy, particularly IL1β,I L 6 ,a n d
IFNα/β, can exert both tumor-inhibiting and tumor-pro-
moting eﬀects (double-edged sword) [87, 88]. On one hand,
IFNα/β and IL1β both can directly act on CD4+ T cells to
enhancetheiractivationanddiﬀerentiation[89–92].Inaddi-
tion, IFNα/β and IL1β can augment antigen presentation
and facilitate priming of T cells [15, 37, 70, 93]. Moreover,
IL6 and IFNα/β can potentiate eﬀector cells to resist Treg-
mediatedsuppression[71,94],andIL6andIL1βcanmediate
Treg →Th17 conversion [95–97]. On the other hand, IL1β
and IL6 have been shown to drive tumorigenesis [98–
103] and dampen host immunity by expanding myeloid-
derived suppressor cells (MDSCs) [104–106]. IFNα/β are
potent inducers of coinhibitory molecules PDL1 [107]a n d
PD1 [108], and immunosuppressive enzyme indoleamine
2,3-dioxygenase (IDO) [109, 110]. Furthermore, it has
been shown that IL6 contributes to chemoresistance [111].
Intriguingly, the eﬃcacy of many cancer therapies is often
associated with certain degree of inﬂammatory responses
[34, 112, 113] .Ar e c e n ts t u d yb yH a a b e t he ta l .h a ss u g g e s t e d
that unopposed inﬂammation may promote tumor progres-
sion while the presence of Th1 cells can tilt inﬂammation
toward eﬀective antitumor immunity [85]. This hypothesis
is supported by the observation that chronic inﬂammation
associated with psoriasis, a Th1-mediated autoimmune
disease aﬀecting the skin, does not promote the development
of skin cancers [114]. Therefore, it is likely that Th1 CD4+
T cells play a critical role in conditioning a tumor-inhibiting
inﬂammatory milieu that facilitates immune activation and
tumor destruction.
3.4.3.MediatingDirectTumorDestruction. Besidesrendering
other immune cells tumoricidal, CD4+ T cells have the
capability to mediate direct tumor destruction. It has been
shown that CD4+ T cells can induce apoptosis in tumor
cells through FAS- or TRAIL-dependent pathway [115, 116].
Moreover, there is accumulating evidence that CD4+ T cells
can acquire cytolytic activities like cytotoxic CD8+ T cells
[117–121]. However, the signiﬁcance of this property has
beenlargelyignored,untilrecentlytwostudieshaveprovided
compelling evidence that cytotoxic CD4+ T cells developed
in a lymphopenic environment can eradicate established
melanoma as a result of direct killing of the tumor cells
through granzyme B [66, 122]. Currently it is unknown
whether cytotoxic CD4+ T cells and helper CD4+ T cells
develop in parallel, or they are the same cells at diﬀerent
stages of diﬀerentiation. Nevertheless, Qui et al. provided
evidence that costimulation through CD134 (OX40) and
CD137 (4-1BB) is required to drive the diﬀerentiation
of cytotoxic CD4+ eﬀector cells in an eomesodermin-
dependent manner [123]. Although cytotoxic CD4+ and
CD8+ T cells appear to mediate tumor killing using the same
eﬀector molecules, such as granzyme B and perforin, they
target MHC-II and MHC-I-restricted antigens, respectively.
One important implication of CD4+ T-cell cytotoxicity is
that CD4+ T-cell-mediated tumor destruction may result
in antigen spreading, which is associated with broadened
antitumor CD8 responses and improved clinical responses
[8, 124–126].Clinical and Developmental Immunology 5
In summary, with an arsenal of diverse cancer-ﬁghting
weapons,CD4+Tcellscanmediatetumordestructioneither
on their own or by cooperating with other immune cells.
Whereas CD4+ T cells alone clearly have the potential to
eﬀe c t i v e l ye r a d i c a t et u m o r s[ 66, 122, 127], the majority of
published studies indicate that the optimal antitumor eﬀects
are achieved when CD4+ T cells act in concert with tumor-
reactive CD8+ T cells [8, 78–80, 128–133], macrophages
[6], or NK cells [7]. A long-held perception is that CD4
antitumor immunity is only relevant to the treatment of
MHC-II+ tumors. Nevertheless, due to the wide-range mode
of actions, CD4+ T cells have been shown to play active and
indispensablerolesincontrollingbothMHC-II+ [63,64]and
MHC-II− tumors [6, 7, 78, 79, 127, 134, 135]. It is worth
noting that some solid tumors, melanoma, for instance, can
be induced to express MHC-II upon encountering IFNγ and
thus become direct targets of CD4+ eﬀector T cells [66, 122].
Therefore, the generation of eﬀective CD4+ T-cell responses
has great therapeutic potential and broad clinical relevance.
4.InhibitoryMechanisms That Attenuate
AntitumorCD4+T-Cell Responses
Tumor-speciﬁc CD4+ T cells are subject to a variety of toler-
izingmechanismsoperativeinthetumormicroenvironment.
Induction of anergy in antigen-speciﬁc CD4+ T cells is an
early event in the course of tumor progression [136]. We and
others show that tumor-antigen recognition is accompanied
with induction of both CD4+ eﬀector cells and Tregs [56, 57,
137]. However, the tolerogenic nature of the tumor milieu
progressively renders CD4+ eﬀector T cells dysfunctional,
characterizedbysustainedexpressionofPD1andheightened
apoptosis [64]. Thus, the anergic phenotype of the overall
CD4 population represents the net result of Treg induction,
eﬀector dysfunction, and active immune suppression. Treg
cells enriched in tumor may come from expansion of
preexisting Tregs, and de novo induction of Treg cells [137,
138], which may occur in both antigen-dependent [138]
and -independent [139] manner in tumor-bearing hosts.
Pertaining to combinatory chemoimmunotherapy, it will be
important to determine if highly activated CD4+ eﬀector T
cells are susceptible to Treg conversion in the face of minimal
residual disease after chemotherapy. Although it has been
shown that polarized Th1 eﬀectorcellsand memory CD4+ T
cells are refractory to conversion to Tregs [140, 141], whether
this is the case in the postchemotherapy setting is yet to be
addressed.
Tregs have been shown to attenuate antitumor responses
throughavarietyofmechanisms,includingdeactivatingDCs
[142,143],preventingCD8+T-cell-mediatedcytolysis[144],
and direct killing of DC, NK, and CD8+ T cells [145, 146].
Importantly, Tregs may operate in concert with other regu-
latory mechanisms, including MDSC, coinhibitory molecule
PD1, and immunosuppressive enzyme IDO, to form a self-
reinforcing immunosuppressive network, posing a severe
threat to the magnitude and durability of an eﬀective
antitumor immune response. MDSCs can act as tolerogenic
APCs to expand Tregs [147, 148]. IDO+ DCs can directly
activate Tregs which subsequently mediate suppression in a
PD1/PDL1-dependent fashion [149]. Programmed death 1
(PD1) was initially found to mediate CD8+ T-cell functional
exhaustion during chronic viral infections [150].Subsequent
studies conﬁrmed the existence of exhausted PD1high CD8+
T cells during tumor progression [151, 152]. However, the
role of PD1 in regulating CD4+ T-cell response in the tumor
context is less clear. Using a mouse B-cell lymphoma model,
we provided clear evidence that PD1high CD4+ T cells consti-
tuted a fraction of tumor antigen-experienced cells and were
associated with downregulation of IL7 receptor and elevated
levelofapoptosis[64].Interestingly,weshowedinthismodel
that PD1 was not required for tumor-driven Treg induction,
while two other studies reported that PDL1 was involved
in peripheral Treg induction and maintenance [153, 154].
Given that PD1 is not the only receptor for PDL1 [155–157],
the seemingly discrepant results suggest that PDL1 on DCs
may diﬀerentially regulate Treg induction and eﬀector T-cell
dysfunction through engaging diﬀerent receptors on CD4+
T cells. This is supported by the observation that PD1 and
Foxp3 have a nonoverlapping expression pattern in CD4+
T cells inﬁltrating B-cell lymphoma [158, 159]. Collectively,
these ﬁndings and the results from other studies [160–163]
support a scenario in which Treg-mediated suppression and
PD1-dependentT-celldysfunctioncontributeindependently
but synergistically to the failed immunological control of
tumor growth.
5. Implications for Combined
Chemoimmunotherapy
Standard chemotherapy is a major treatment option for
many types of cancer. It can eﬀectively treat the symptom of
cancer initially, but frequently its eﬃcacy is compromised by
late tumor recurrence. The ability of some anticancer drugs
to drive productive CD4+ T-cell responses, and the versatile
and pivotal roles of CD4+ eﬀector T cells in mediating
antitumor eﬀects, provide strong rationales for developing
a strategy that utilizes CD4+ eﬀector T cells to strengthen
and sustain the postchemotherapy antitumor immunity.
This can be achieved clinically through the combination of
chemotherapy and adoptive immunotherapy or therapeutic
vaccination. Indeed, the eﬃcacy of this strategy has been
hinted by some elegant clinical studies, which showed that
better immunological and clinical responses were obtained
in melanoma or myeloma patients that had received CD4+
T cell-containing donor cells following preconditioning
chemotherapy [129, 131].
To overcome tumor-induced immune tolerance, addi-
tional maintenance regimens are needed to keep CD4+
T cells in the polyfunctional eﬀector state. Many of the
currently available immune modulators [164], such as
recombinant IL7, CD40 agonist, PD1 blockade, and CTLA4
blockade,canbeappliedtopotentiateandsustainCD4eﬀec-
tors in addition to enhancing antitumor CD8 responses. We
showed that polyfunctional CD4+ T cells have the unusual
distinguishing attribute of high levels of IL7 receptor expres-
sion [64], suggesting that these cells can be preferentially6 Clinical and Developmental Immunology
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Figure 1: Hypothetical model of the mutually reinforcing eﬀect of chemotherapy and antitumor CD4+ eﬀector T cells. Chemotherapy
reduces tumor burden, releases tumor antigens, and induces inﬂammation. In this highly immunogenic milieu created after chemotherapy,
therapeutic immunological maneuvers such as adoptive cell therapy (ACT) using tumor-reactive CD4+ T cells or cancer vaccines can lead to
the generation of highly activated CD4+ eﬀector T cells with polyfunctional activities. These CD4+ eﬀe c t o rTc e l l sa c ta st h e“ g a t e k e e p e r s ”
of the overall antitumor immunity in postchemotherapy hosts, by helping the activation and function of other immune cells (CD8, DC, and
macrophage) and directly attacking the tumor cells. In addition, cytokines produced by CD4+ eﬀe c t o rTc e l l s( I F N γ and TNFα)m a ya l s o
target and destroy tumor stroma and thus inhibit tumor angiogenesis. These diverse immune responses superimpose to eﬀectively eradicate
residual tumors. In contrast, without properly activated CD4+ eﬀector T cells, an eﬀective host antitumor immunity may not be elicited or
is not sustainable, leading to tumor persistence and eventual relapse.
expanded by supplying exogenous IL7. Moreover, activating
DCs with an anti-CD40 agonist antibody can prevent CD4+
T-cell tolerance [165]. PD1 blockade, currently undergoing
extensive clinical trials for a variety of cancers [166, 167], is
largely expected to restore CD8+ T-cell antitumor function
but may as well beneﬁt CD4+ eﬀector T cells. Notably,
CTLA4 blockade with ipilimumab, recently approved by
FDA for the treatment of late-stage melanoma, has been
shown to promote the generation of polyfunctional CD4+
T cells in response to vaccination [168].
With regard to alleviating Treg-mediated immunosup-
pression, current approaches only have limited success in
therapeutic settings. Low-dose CTX reduces and inacti-
vates Tregs, but doing so only transiently. Application of
denileukin diftitox (Ontak) did not result in consistent clin-
ical outcomes [169, 170], likely due to its eﬀect on both
eﬀector T cells and Tregs. Findings from some recent studies
suggestnew strategies for disarming Tregs. It has been shown
that combined use of CTX and an agonist antibody targeting
the costimulatory receptor OX40 can result in intratumoral
apoptosis of Tregs [42] .M o r e o v e r ,S h a r m ae ta l .r e p o r t e d
that disrupting the IDO pathway with clinically applicable
pharmacological inhibitors can reprogram Tregs to Th17
cells [171].
Altogether, a successful combined chemoimmunother-
apy should integrate strategies that target multiple mutu-
ally reinforcing immune pathways that converge to attain
productive CD4 eﬀector responses, thereby maintaining a
durable and eﬀective antitumor immunity after chemother-
apy.
6. Conclusions
Although the concept of combined chemoimmunotherapy
for cancer can be dated back to at least three decades ago
[10, 11], its clinical application started to gain momentum
only in recent years when the mechanistic basis for the
synergy between chemotherapy and immunotherapy began
to be unveiled at the cellular and molecular level. The
emerging evidence that chemotherapy can profoundly drive
the eﬀector development of tumor-speciﬁc CD4+ T cells
implicates a new direction for chemoimmunotherapy, which
aims to capitalize on the antitumor potential of CD4+
eﬀector T cells. In light of the unique and pivotal roles of
tumor-reactive CD4+ eﬀector T cells, we propose a scenario
in which CD4+ eﬀector T cells act as the “gatekeepers” of
the overall host antitumor immunity after chemotherapy,
whose functional status (polyfunctional versus tolerized)
criticallydeterminestheoutcomebetweeneradicationversus
recurrence of residual tumors (Figure 1). Further studies are
needed to explore additional CD4+ T cell-potentiating anti-
cancer drugs and establish clinically applicable strategies for
maximum utilization of the synergy between chemotherapy
and antitumor CD4 eﬀector responses in order to achieve
durable therapeutic eﬃcacy.
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